White House issues a national DNA synthesis screening policy, citing super intelligence uplift

On November 5, 2026, the White House issued NSTM-6, a memorandum from National Security Advisor Marco Rubio and OSTP Director Michael Kratsios implementing the 2026 National Policy for Nucleic Acid Synthesis Screening under Executive Order 14292. The policy replaces the 2024 Framework for Nucleic Acid Synthesis Screening and, once fully implemented, the 2023 HHS screening guidance.

The memo frames the policy around AI. It says the United States “stands at the threshold of a profound transformation driven by the convergence of super intelligence (SI) and biology”, that synthetic nucleic acids could supply the raw materials for biological threats, and that the policy creates a screening layer that keeps pace with risks “including those from SI uplift”. It also criticises existing guidance for relying on self-attestation rather than independent verification.

The policy requires all recipients of federal life sciences funding to buy synthetic nucleic acids and benchtop synthesis equipment only from adherent suppliers. A supplier is adherent when it runs every order through a NIST-verified screener, performs know-your-customer checks, reports flagged orders to federal authorities such as the FBI, and keeps screening records. Screening targets orders of 50 or more nucleotides. Within 90 days NIST is to issue standards and test protocols; HHS is to publish the first list of adherent suppliers within 160 days; funded customers must buy all synthetic nucleic acids from certified suppliers within 250 days and all benchtop equipment within 340 days.

Why it matters: AI-enabled biological misuse is one of the main risks cited by frontier labs and safety institutes. This is a binding federal funding condition, with independent verification of screeners, aimed at the physical choke point between a model’s output and a real pathogen.

What it does not show: the policy binds only recipients of federal funds, not every buyer of synthetic DNA. The NIST standards and the supplier list do not exist yet, and the claim that screening will shift from list-based to risk-based through SI is a stated intention, not a demonstrated capability.